Study Stopped
PI leaving for another institution.
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior
NicWith
1 other identifier
interventional
21
1 country
1
Brief Summary
This study is designed to find out how smoking affects the way the brain responds to pleasure and how this impacts smokers' behavior. Participants will complete three sessions. The first session will be a screening and training visit to determine final eligibility. Eligible participants will work with a researcher to develop brief scripts about times when they smoke and do other activities. Next, participants will attend two magnetic resonance imaging (MRI) scans - one after abstaining from smoking for 24 hours and the other after smoking as usual. After the second MRI, participants will answer questions on their phone every day for two weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 12, 2019
CompletedFirst Posted
Study publicly available on registry
February 15, 2019
CompletedStudy Start
First participant enrolled
September 10, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 13, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 13, 2021
CompletedMay 20, 2021
May 1, 2021
1.7 years
February 12, 2019
May 18, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Blood Oxygen Level Dependent (BOLD) Activation
BOLD activation in brain reward network regions
Approximately 1-3 weeks
Ecological Momentary Assessment (EMA) Pleasure Ratings
Anticipated and actual pleasure ratings acquired each day during EMA portion of study. Individual items are based on the 12-item Tripartite Pleasure Inventory (TPI). Participants rate their anticipated pleasure for activities they expect to engage in each day using a 0 (No pleasure) to 4 (Extreme pleasure) scale in the morning. They will then rate their actual experienced pleasure for activities they actually did engage in the evening using the same scale. Scores are summed across items for a theoretical range of 0-48.
2-6 weeks
Study Arms (2)
Smoking Abstinence
OTHERParticipants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
Ad Lib Smoking
OTHERParticipants will continue smoking as usual (i.e. "ad lib") before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing.
Interventions
Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
Eligibility Criteria
You may qualify if:
- Generally healthy
- Right-handed
- Smoke \>= 10 cigarettes per day
- Smoking regularly for \>= 1 year
- Carbon Monoxide (CO) \> 8 at screening (or urinary cotinine \> 100)
- Own a compatible smartphone
- Able to read and understand English
- Able to identify at least 4 pleasurable activities they do not do concurrently with smoking or associate with smoking
You may not qualify if:
- Regular use of "roll your own" cigarettes
- Planning to quit smoking within the next 60 days
- Current or planned smoking cessation treatment
- Regular use of smokeless tobacco or other nicotine products
- Expired CO \> 80 parts per million
- Breath alcohol \> .000 at screening (re-attempts are allowed)
- Significant medical problems
- Currently breastfeeding, pregnant, or planning to become pregnant
- Enrollment in another study utilizing Spectrum cigarettes within the last 3 months
- Irregular slee-wake cycles (e.g. swing-shift work, unusual sleep patterns)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duke Universitylead
- National Institutes of Health (NIH)collaborator
- National Institute on Drug Abuse (NIDA)collaborator
- Food and Drug Administration (FDA)collaborator
Study Sites (1)
Duke University School of Medicine
Durham, North Carolina, 27705, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jason A Oliver, PhD
Duke University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 12, 2019
First Posted
February 15, 2019
Study Start
September 10, 2019
Primary Completion
May 13, 2021
Study Completion
May 13, 2021
Last Updated
May 20, 2021
Record last verified: 2021-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- We anticipate making data available within 6 months of study completion. It will be available for an indefinite period of time.
- Access Criteria
- Contact PI for details.
Detailed protocols, datasets and additional information will be available from the Principal Investigator and research team upon request. In order to maintain compliance with the Health Insurance Portability and Accountability Act (HIPAA) requirements, as well as university data security policies, all data will be anonymized according to HIPAA guidelines prior to being shared. Individual participant scripts will not be made publicly available due to privacy concerns and because this could impact the nature of information participants were willing to provide for scripts. Data will be provided in widely accessible formats for both self-report and imaging data. We will work with the Office of Research Contracts to obtain guidance regarding any required Data Use Agreements as needed.